Muslim Brotherhood founder’s grandson Tariq Ramadan hospitalized while facing rape charges

Muslim Brotherhood founder’s grandson Tariq Ramadan hospitalized while facing rape charges
Two Muslim women have accused Tariq Ramadan, a 55-year-old Oxford University professor whose grandfather founded Egypt’s Muslim Brotherhood movement, of rape. (AFP)
Updated 17 February 2018

Muslim Brotherhood founder’s grandson Tariq Ramadan hospitalized while facing rape charges

Muslim Brotherhood founder’s grandson Tariq Ramadan hospitalized while facing rape charges

PARIS: Prominent Islamic scholar Tariq Ramadan, who was remanded in custody in France on rape charges earlier in the month, has been hospitalized due to multiple sclerosis, his support group said Saturday.
The 55-year-old Oxford University professor, who will now undergo an independent medical evaluation to determine if he is to remain in jail before trial, was sent to hospital on Friday night, a source close the case confirmed.
“His state of health is getting worse, particularly since the judges refused to issue a visit permit to his wife and children yesterday,” a source close to Ramadan said on Saturday.
His lawyers said that their client’s condition was “not compatible with detention,” based on an initial medical examination on Tuesday.
Charged with rape and rape of a vulnerable person, Ramadan had been held at the Fleury-Merogis prison near Paris since February 2.
A court ordered Ramadan be detained ahead of his trial, saying he was a possible flight risk and fearing potential pressure on women who testified anonymously.
A Paris appeals court ordered the medical evaluation on Thursday and postponed its ruling on his detention until February 22 after Ramadan went to the hearing in an ambulance.
The arrest of the influential academic — a regular on TV debates with more than two million Facebook followers — has rocked the French Muslim community.
Two Muslim women have accused Ramadan, a Swiss citizen whose grandfather founded Egypt’s Muslim Brotherhood movement, of rape.
They went public with the allegations late last year when women began sharing accounts of sexual harassment and assault as part of the “Me Too” and “Balance Ton Porc” (Expose your pig) campaign triggered by the revelations against Hollywood mogul Harvey Weinstein.
Ramadan, who took leave of absence from Oxford in November after the allegations surfaced, is the most high-profile figure to be held in France since the campaign began.
Henda Ayari, a 41-year-old feminist activist who previously practiced an ultra-conservative brand of Islam, claims Ramadan raped her in Paris in 2012.
Another woman, a 40-year-old disabled Muslim convert going by the alias “Christelle,” claimed he raped and beat her in the southeastern city of Lyon in 2009.
The married father of four has rejected the accusations saying he is the victim of a smear campaign.


Russia’s second coronavirus vaccine ‘100% effective’, watchdog tells media

Russia’s second coronavirus vaccine ‘100% effective’, watchdog tells media
Updated 11 min 48 sec ago

Russia’s second coronavirus vaccine ‘100% effective’, watchdog tells media

Russia’s second coronavirus vaccine ‘100% effective’, watchdog tells media
  • ‘The effectiveness of the vaccine is made up of its immunological effectiveness and preventative effectiveness’

MOSCOW: A candidate COVID-19 vaccine known as EpiVacCorona, Russia’s second to be registered, proved “100 percent effective” in early-stage trials, Russian consumer health watchdog Rospotrebnadzor has told local media.
The data, based on Phase I and II trials, were released before the start of a larger Phase III trial which would normally involve thousands of participants and a placebo group as a comparison.
“The effectiveness of the vaccine is made up of its immunological effectiveness and preventative effectiveness,” the TASS news agency reported, citing Rospotrebnadzor.
“According to results of the first and second phases of clinical trials, the immunological effectiveness of the EpiVacCorona vaccine is 100 percent.”
The Phase I and II studies tested the safety, reactogenicity and immunogenicity of the potential vaccine in 100 people aged 18-60, according to the state trials register.
Russia began testing EpiVacCorona, which is being developed by Siberia’s Vector Institute, in November.
Earlier that month, Moscow said its other approved vaccine, Sputnik V, was 92 percent effective at protecting people from COVID-19 based on interim results.
Russia has said it can inoculate 60 percent of its population against COVID-19 this year, and although the Sputnik V vaccine has been readily available in Moscow, the rollout across the country has been slow.
Russian President Vladimir Putin has ordered mass vaccinations to start this week.
EpiVacCorona will be used in mass vaccinations from March, Deputy Prime Minister Tatiana Golikova told the Interfax news agency.
Russia has reported 3,612,800 coronavirus cases, the world’s fourth-highest total. Its death toll from the virus stands at 66,623.